[2]
Worldometer. Coronavirus Cases. Worldometer 2020; 1-22 Avai lable from: https://www.worldometers.info/coronavirus/.
[8]
Health Services A. COVID-19 Scientific Advisory Group Rapid Evidence Report. 2020; 32: 15-20.
[26]
Deretic V, Timmins GS. Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells. bioRxiv 2020.
[28]
Gbinigie K, Frie K. What is the evidence for using macrolide antibiotics to treat COVID-19. 2020; 2020. Available from: https: //www.cebm.net/covid-19/what-is-the-evidence-for-use-of- macrolide-antobiotics-for-treatmetnof-covid-19/.
[35]
Duška F, Waldauf P, Halačová M, Zvoníček V, Bala J, Beneš J. Azithromycin added to Hydroxychloroquine for Patients Admitted to Intensive Care due to Coronavirus Disease 2019 (COVID-19) – Protocol of Randomized Controlled Trial AZIQUINE-ICU. Res Sq 2020; 2019: 1-20.
[53]
Grayson ML, Crowe SM, McCarthy JS, Mills J, Mouton JW, Norrby SR. Kucers’ the use of antibiotics sixth edition: A clinical review of antibacterial. Antifungal and Antiviral Drugs 2010; 3223.
[55]
Mansilla E, Martínez RR, Marín GH, Filho IZ, Rivas E, Rivas J. Macrolide-clarithromycin task-force for the treatment and prophylaxis of Covid-19 as a single agent. Pharmacol &. Pharm 2020; 11(06): 85-104.
[56]
Zakeri B, Wright GD. Chemical biology of tetracycline antibiotics. Biochem Cell Biol 2008; 86(2): 124-36.
[70]
Patel AR, Patra F, Shah NP, Shukla D. Biological control of mycotoxins by probiotic lactic acid bacteria. Dynamism dairy Ind Consum demands 2017; 2015(February): 2-4.
[78]
fda, cder. MINOCIN ® (minocycline hydrochloride) Pellet-Filled Capsules only.
[85]
Diana G, Strollo R, Diana D, Strollo M, Galassi AR, Crea F. Cardiac safety and potential efficacy: Two reasons for considering minocycline in place of azithromycin in COVID-19 management. Eur Hear J Cardiovasc Pharmacother 2021; 7(3): e53-4.
[97]
Venkataraman N, Cole AL, Ruchala P, Waring AJ, Lehrer RI, Stuchlik O. Reawakening retrocyclins: Ancestral human defensins active against HIV-1. PLoS Biol 2009; 7(4): 0720-9.
[104]
Cowling T, Farrah K. Fluoroquinolones for the treatment of respiratory tract infections: A review of clinical effectiveness, cost-effectiveness, and guidelines.Guidel 2019; pp. 1-36.
[113]
Miravitlles M, Anzueto A. Moxifl oxacin : A respiratory fl uoroquinolone. Expert Opin Pharmacother 2008; 1755-72.
[114]
Qin X, Qiu S, Yuan Y, Zong Y, Tuo Z, Li J. Clinical characteristics and treatment of patients infected with COVID-19 in Shishou, China. China 2020.
[117]
Dayer MR. Old drugs for newly emerging viral disease, Covid-19: Bioinformatic prospective. 2020.
[124]
Yongwei Zhao Y T. Understanding the glycopeptide antibiotic crosslinking cascade – in vitro approaches revealing the details of a complex biosynthesis pathway. ChemBioChem 2021; 22(1): 43-51.
[131]
Liu SuNan, Li W. Respective analysis of teicoplanin in the treatment of bacterial pneumonia secondary to COVID-19. Respective Anal teicoplanin Treat Bact pneumonia Second to COVID-19 2021.
[135]
Singh H, Chauhan P, Singh J. Concomitant use of dexamethasone and tetracyclines: A potential therapeutic option for the management of severe COVID-19 infection? 2021; 14(3): 315-22.